- Home
- ABVC vs RLMD Comparison
ABVC vs RLMD Comparison
Compare ABVC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- RLMD
- Stock Information
- Founded
- ABVC 2015
- RLMD 2004
- Country
- ABVC United States
- RLMD United States
- Employees
- ABVC N/A
- RLMD N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- RLMD Health Care
- Exchange
- ABVC Nasdaq
- RLMD Nasdaq
- Market Cap
- ABVC 22.1M
- RLMD 22.0M
- IPO Year
- ABVC N/A
- RLMD N/A
- Fundamental
- Price
- ABVC $2.19
- RLMD $0.67
- Analyst Decision
- ABVC
- RLMD Buy
- Analyst Count
- ABVC 0
- RLMD 3
- Target Price
- ABVC N/A
- RLMD $5.00
- AVG Volume (30 Days)
- ABVC 312.1K
- RLMD 478.7K
- Earning Date
- ABVC 08-13-2025
- RLMD 08-06-2025
- Dividend Yield
- ABVC N/A
- RLMD N/A
- EPS Growth
- ABVC N/A
- RLMD N/A
- EPS
- ABVC N/A
- RLMD N/A
- Revenue
- ABVC $508,383.00
- RLMD N/A
- Revenue This Year
- ABVC $735.18
- RLMD N/A
- Revenue Next Year
- ABVC N/A
- RLMD N/A
- P/E Ratio
- ABVC N/A
- RLMD N/A
- Revenue Growth
- ABVC 1904.43
- RLMD N/A
- 52 Week Low
- ABVC $0.40
- RLMD $0.24
- 52 Week High
- ABVC $2.29
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- ABVC 70.75
- RLMD 52.84
- Support Level
- ABVC $1.84
- RLMD $0.67
- Resistance Level
- ABVC $2.29
- RLMD $0.72
- Average True Range (ATR)
- ABVC 0.16
- RLMD 0.08
- MACD
- ABVC 0.03
- RLMD -0.03
- Stochastic Oscillator
- ABVC 87.65
- RLMD 40.29
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.